NDAORALTABLET
Approved
Nov 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Diethylcarbamazine citrate (HETRAZAN) is an oral anthelmintic tablet approved since 1950 by Pfizer. It is used to treat parasitic infections, particularly filarial worm infections including lymphatic filariasis and onchocerciasis. The drug works by immobilizing and killing parasitic worms through microfilaricidal action.
LOE Approaching
Product is in advanced lifecycle stage with significant patent cliff risk; commercial teams are likely focused on defending market share rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and approaching loss of exclusivity, career opportunities on HETRAZAN are limited and declining. Working on this product offers defensive market management experience rather than growth-oriented career development.
Brand ManagerRegional Sales Manager
Worked on HETRAZAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.